Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure

European Journal of Heart Failure

Volumn 1, Issue 1, 2000, Pages 67-72

  Northridge, David B ^a   Currie, Peter F ^b   Newby, David E ^b   McMurray, John J V ^c   Ford, Michael ^c   Boon, Nicholas A ^b   Dargie, Henry J ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

ACE inhibition; Candoxatril; Chronic heart failure; Exercise capacity; NEP inhibition

Indexed keywords

CANDOXATRIL; CAPTOPRIL;

ADULT; AGEUSIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; EXERCISE TEST; EXERCISE TOLERANCE; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; STOMATITIS; TREADMILL EXERCISE; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INDANS; MALE; MIDDLE AGED; PROPIONATES; PROTEASE INHIBITORS;

EID: 0033086884     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(98)00003-8     Document Type: Article

References (24)

1. Richards AM, Nicholls MG, Ikram H et al. Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985;ii:545-549.
2. Roy LF, Ogilvie RI, Larochelle P et al. Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men. Circulation 1989;79:383-392.
3. Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 1990;81:1860-1873.
4. Cody RJ, Atias SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-1374.
5. Fifer MA, Molina CR, Quiroz AC et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1990;65:211-215.
6. Munzel T, Drexler H, Holtz J et al. Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation 1991;83:191-201.
7. Shepperson NB, Barclay PL, Bennet JA et al. Inhibition of neutral endopeptidase (EC3.4 24.11) leads to an atrial natriuretic factor-mediated natriuretic, diuretic and antihypertensive response in rodents. Clin Sci 1991;80:265-269.
8. Northridge DB, Jardine AG, Alabaster CT et al. Effects of UK 69578: A novel atriopeptidase inhibitor. Lancet 1989;ii:591-593.
9. Richards M, Espiner E, Ikram H et al. Inhibition of endopeptidase EC 24.11 in humans: Renal and endocrine effects. Hypertension 1990;16:269-276.
10. Elsner D, Muntze A, Kromer EP et al. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-498.
11. Narang R, Swedberg K, Cleland JGF. What is the ideal design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-134.
12. Northridge DB, Grant S, Ford I et al. Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J 1990;64:313-316.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
14. Rodeheffer RJ, Tanaka I, Imada T, Hollister AS, Robertson D, Inagami T. Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. J Am Coll Cardiol 1986;8:18-26.
15. Edwards BS, Zimmerman RS, Schwab TR, Heublen DM, Burnett JC. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988;63:191-195.
16. Wada A, Tsutamoto T, Matsuda Y et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994;89:2232-2240.
17. Drexler H, Hirth C, Stasch HP et al. Vasodilatory action of endogenous atrial natriuretic peptide in a rate model of chronic heart failure as determined by ANF antibody. Circ Res 1990;66:1371-1380.
18. Northridge DB, McMurray J, Dargie HJ. Atrial natriuretic factor in chronic heart failure. Herz 1991;16:92-101.
19. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG, Dargie HJ. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens 1990;3:682-687.
20. Creager MA, Massie BM, Faxon DP et al. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 1985;6:163-173.
21. Levine TB, Olivari MT, Garberg V, Sharkey SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984;69:548-553.
22. Sullivan M, Atwood E, Myers J et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol 1989;13:1138-1143.
23. Groban L, Cowley AW, Ebert TJ. Atrial natriuretic factor augments forearm capillary filtration in humans. Am J Physiol 1990;259:H258-H263.
24. Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998;19:1808-1813.